# Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

> **NCT06991101** · PHASE2 · RECRUITING · sponsor: **Baptist Health South Florida** · enrollment: 190 (estimated)

## Conditions studied

- Glioblastoma
- Brain Cancer
- Glioblastoma Multiforme
- Glioblastoma Multiforme of Brain
- Glioblastoma Multiforme, Adult
- MGMT-Unmethylated Glioblastoma
- MGMT-Methylated Glioblastoma

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Temozolomide
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT06991101
- **Lead sponsor:** Baptist Health South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06991101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06991101, "Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06991101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*